Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India

Introduction Programmed death ligand-1 (PD-L1) is an immunological checkpoint that supports the inhibition of the anti-tumor immune system. A higher level of PD-L1 expression was also discovered on the cell surfaces of several cancer cells, including non-small cell lung carcinoma (NSCLC). Identifyin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganie, Firdous, Mehfooz, Nazia, Siraj, Farhana, Khan, Umar H, Mantoo, Suhail, Dhar, Amrit, Mir, Mohmad Hussain, Jan, Rafi A, Shah, Sonaullah, Qadri, Syed Mudasir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024510/
https://www.ncbi.nlm.nih.gov/pubmed/36942175
http://dx.doi.org/10.7759/cureus.35056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024510/
https://www.ncbi.nlm.nih.gov/pubmed/36942175
http://dx.doi.org/10.7759/cureus.35056

Ejemplares similares